keyword
https://read.qxmd.com/read/38506810/attention-deficit-hyperactivity-disorder-medications-and-work-disability-and-mental-health-outcomes
#1
JOURNAL ARTICLE
Heidi Taipale, Jakob Bergström, Katalin Gèmes, Antti Tanskanen, Lisa Ekselius, Ellenor Mittendorfer-Rutz, Magnus Helgesson
IMPORTANCE: Individuals with attention-deficit/hyperactivity disorder (ADHD) often have comorbid psychiatric conditions. Relatively little is known about how specific ADHD medications are associated with overall treatment outcomes among these patients. OBJECTIVE: To investigate the association of the use of specific ADHD medications with hospitalization outcomes and work disability among adolescents and adults with ADHD. DESIGN, SETTING, AND PARTICIPANTS: This nationwide register-based cohort study identified individuals (aged 16-65 years) with ADHD from Swedish nationwide registers of inpatient health care, specialized outpatient health care, sickness absence, and disability pension during the years 2006 to 2021...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38433530/efficacy-and-safety-of-established-and-off-label-adhd-drug-therapies-for-cognitive-impairment-or-attention-deficit-hyperactivity-disorder-symptoms-in-bipolar-disorder-a-systematic-review-by-the-isbd-targeting-cognition-task-force
#2
REVIEW
Kamilla W Miskowiak, Zacharias K Obel, Riccardo Gugliemo, Caterina Del Mar Bonnin, Christopher R Bowie, Vicente Balanzá-Martínez, Katherine E Burdick, Andre F Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Lars V Kessing, Beny Lafer, Kathryn E Lewandowski, Carlos López-Jaramillo, Anabel Martinez-Aran, Roger S McIntyre, Richard J Porter, Scot E Purdon, Ayal Schaffer, Paul R A Stokes, Tomiki Sumiyoshi, Ivan J Torres, Tamsyn E Van Rheenen, Lakshmi N Yatham, Allan H Young, Eduard Vieta, Gregor Hasler
BACKGROUND: Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD. METHODS: We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures...
March 3, 2024: Bipolar Disorders
https://read.qxmd.com/read/38363934/idiopathic-hypersomnia-with-a-video-recording-of-a-spontaneous-sleep-attack-a-case-report
#3
JOURNAL ARTICLE
Takamasa Asaga, Kenichi Hashimoto, Yusuke Kawamura, Naoya Fujita, Motohiro Kimata, Akinori Sekizawa, Yosuke Ono, Yasuhiro Obuchi, Nanase Kobayashi, Hideto Hirasawa, Takashi Kanbayashi, Yuji Tanaka
RATIONALE: Although patients with central disorders of hypersomnolence (CDH) exhibit characteristic symptoms of hypersomnia frequently, it takes 5 to 15 years from the onset for its diagnosis due to the lack of symptom recognition. Here, we present a case of idiopathic hypersomnia (IH), a CDH, wherein early diagnosis was aided by a video footage of a spontaneous sleep attack. PATIENT CONCERNS: A 21-year-old man lost consciousness while driving and experienced an accident...
February 16, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/37194538/-psychostimulants-an-overview
#4
JOURNAL ARTICLE
Shintaro Fukumoto, Eiji Imanari, Shinji Tomari, Takuma Higashi, Hirotaka Kosaka
Treatment of narcolepsy is based on the need to regulate life rhythms. Psychostimulants such as modafinil, methylphenidate-immediate release, and pemoline are used to treat hypersomnia. A psychosocial approach is considered the mainstay of treatment for attention-deficit/hyperactivity disorder (ADHD), and medication is used to treat moderate or severe ADHD symptoms. Two of the four drugs approved in Japan for ADHD therapy (osmotic-release oral system methylphenidate and lisdexamfetamine dimesylate) are psychostimulants, which are administered via the ADHD proper distribution management system...
May 2023: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://read.qxmd.com/read/37061629/pharmacologic-management-of-cognitive-disengagement-syndrome-cds-and-implications-for-attention-deficit-hyperactivity-disorder-adhd-treatment-emerging-treatments-and-recommendations-for-future-research
#5
JOURNAL ARTICLE
Kelsey K Wiggs, Tanya E Froehlich, Stephen P Becker
Although the study of cognitive disengagement syndrome (CDS; previously called sluggish cognitive tempo) first emerged in the 1980s, very little is known about treating CDS or its impact on evidence-based interventions for attention-deficit/hyperactivity disorder (ADHD) with which it frequently co-occurs. The objective of this leading article was to investigate the existing evidence on medication treatment and CDS, including studies that have examined CDS response to medication and CDS as a moderator of ADHD treatment response...
April 2023: CNS Drugs
https://read.qxmd.com/read/36759544/in-utero-exposure-to-adhd-medication-and-long-term-offspring-outcomes
#6
JOURNAL ARTICLE
Kathrine Bang Madsen, Thalia K Robakis, Xiaoqin Liu, Natalie Momen, Henrik Larsson, Julie Werenberg Dreier, Helene Kildegaard, Jane Bjerg Groth, Jeffrey H Newcorn, Per Hove Thomsen, Trine Munk-Olsen, Veerle Bergink
Attention Deficit Hyperactivity Disorder (ADHD) medication is increasingly being used during pregnancy. Concerns have been raised as to whether ADHD medication has long-term adverse effects on the offspring. The authors investigated whether in utero exposure to ADHD medication was associated with adverse long-term neurodevelopmental and growth outcomes in offspring. The population-based cohort study in the Danish national registers included 1,068,073 liveborn singletons from 1998 to 2015 followed until any developmental diagnosis, death, emigration, or December 31, 2018...
April 2023: Molecular Psychiatry
https://read.qxmd.com/read/36421870/pharmacological-treatments-for-cocaine-craving-what-is-the-way-forward-a-systematic-review
#7
REVIEW
Dângela Layne Silva Lassi, André Malbergier, André Brooking Negrão, Lígia Florio, João P De Aquino, João Maurício Castaldelli-Maia
BACKGROUND: cocaine craving is a core feature of cocaine use disorder and remains a critical challenge for abstinence and relapse prevention. This review summarizes the anti-craving efficacy of pharmacotherapies tested for cocaine use disorder, in the context of randomized-controlled clinical trials. OBJECTIVES: we assessed the databases of the U.S. National Library of Medicine, Google Scholar, and PsycINFO, without date restrictions up to August 2022, to identify relevant studies...
November 14, 2022: Brain Sciences
https://read.qxmd.com/read/36294540/chondral-desmal-osteogenesis-in-3d-spheroids-sensitized-by-psychostimulants
#8
JOURNAL ARTICLE
Nele Wagener, Wolfgang Lehmann, Kai O Böker, Eric Röhner, Pietro Di Fazio
Attention deficit hyperactivity disorder (ADHD) affects 6.4 million children in the United States of America. Children and adolescents, the main consumers of ADHD medication, are in the bone growth phase, which extends over a period of up to two decades. Thus, impaired proliferation and maturation of chondrocytes and osteoblasts can result in impaired bone formation. The aim of this study is to investigate, for the first time, the effects of the ADHD-medication modafinil, atomoxetine and guanfacine on bone growth and repair in vitro...
October 21, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/36204437/the-effect-of-long-acting-methylphenidate-and-modafinil-on-attention-and-impulsivity-of-children-with-adhd-using-a-continuous-performance-test-a-comparative-study
#9
JOURNAL ARTICLE
Ghazal Zahed, Maliheh Roozbakhsh, Rozita Davari Ashtiani, Katayoun Razjouyan
Objectives: Given the importance of having a continuous performance for the academic and social life of children with attention-deficit/hyperactivity disorder (ADHD), in this study, a Continuous Performance Test (CPT) was used to compare the effect of long-acting methylphenidate and modafinil on attention and impulsivity of these children. Materials & Methods: A randomized clinical trial was conducted on 50 children with ADHD aged 6 to 12 years in the child and adolescent psychiatric departments of Imam Hossein and Mofid hospitals, Tehran, Iran...
2022: Iranian Journal of Child Neurology
https://read.qxmd.com/read/36148571/could-modafinil-be-an-option-in-the-treatment-of-sexual-dysfunctions-due-to-antidepressant-use-in-women-two-case-reports
#10
JOURNAL ARTICLE
Barış Yilbaş
Antidepressants are known to cause sexual dysfunctions. Sexual side effects due to antidepressants negatively affect compliance with treatment. Modafinil is a stimulant drug used for narcolepsy and some other sleep disorders. It is also used in treatment of resistant depression, chronic fatigue syndrome, attention deficit hyperactivity disorder, and cocaine addiction syndrome. In this article, two female patients whose depressive complaints improved with antidepressant treatment, but who applied to the psychiatry outpatient clinic with complaints of sexual dysfunction and daytime sleepiness, will be presented...
2022: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://read.qxmd.com/read/36142172/psychostimulants-modafinil-atomoxetine-and-guanfacine-impair-bone-cell-differentiation-and-msc-migration
#11
JOURNAL ARTICLE
Nele Wagener, Wolfgang Lehmann, Lukas Weiser, Katharina Jäckle, Pietro Di Fazio, Arndt F Schilling, Kai O Böker
Attention deficit hyperactivity disorder (ADHD) is one of the most common worldwide mental disorders in children, young and adults. If left untreated, the disorder can continue into adulthood. The abuse of ADHD-related drugs to improve mental performance for studying, working and everyday life is also rising. The potentially high number of subjects with controlled or uncontrolled use of such substances increases the impact of possible side effects. It has been shown before that the early ADHD drug methylphenidate influences bone metabolism negatively...
September 6, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/35743046/modafinil-administration-to-preadolescent-rat-impairs-non-selective-attention-frontal-cortex-d-2-expression-and-mesolimbic-gaba-levels
#12
JOURNAL ARTICLE
Valeska Cid-Jofré, Macarena Moreno, Ramón Sotomayor-Zárate, Gonzalo Cruz, Georgina M Renard
The misuse of psychostimulants is an increasing behavior among young people, highlighting in some countries the abuse of modafinil (MOD) as a neuropotentiator. However, several clinical trials are investigating MOD as an alternative pharmacological treatment for attentional deficit and hyperactivity disorder (ADHD) in children and adolescents. On the other hand, the early use of psychostimulants and the misdiagnosis rates in ADHD make it crucial to investigate the brain effects of this type of drug in young healthy individuals...
June 13, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/35318300/-trend-in-medicines-use-for-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-2010-2019
#13
JOURNAL ARTICLE
Beatriz Prieto Antolín, Eduardo Gutiérrez-Abejón, Susana Alberola López, Jesús María Andrés de Llano
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD) is a common childhood neurodevelopmental disorder characterised primarily by three core symptoms: inattention, hyperactivity and impulsivity. It is one of the most commonly diagnosed childhood psychiatric disorders, with a worldwide prevalence of between 3% and 5%, and between 6% and 7% in the Spanish population. The aim of the study is to analyse the trend in the consumption of drugs used for the treatment of ADHD between 2010-2019 in Castilla y León...
March 23, 2022: Revista Española de Salud Pública
https://read.qxmd.com/read/34647651/modafinil-rescues-repeated-morphine-induced-synaptic-and-behavioural-impairments-via-activation-of-d1r-erk-creb-pathway-in-medial-prefrontal-cortex
#14
JOURNAL ARTICLE
Fangyuan Yin, Jinyu Zhang, Ye Lu, Yulei Zhang, Jincen Liu, Cuola Deji, Xiaomeng Qiao, Keqiang Gao, Min Xu, Jianghua Lai, Yunpeng Wang
Long-term opioid abuse causes a variety of long-lasting cognitive impairments such as attention, impulsivity and working memory. These cognitive impairments undermine behavioural treatment for drug abuse and lead to poor treatment retention and outcomes. Modafinil is a wake-promoting drug that shows potential in improving attention and memory in humans and animals. However, modafinil's effect on opioid-induced cognitive impairments remains unclear, and the underlying mechanism is poorly understood. This study showed that repeated morphine administration significantly impairs attention, increases impulsivity and reduces motivation to natural rewards in mice...
January 2022: Addiction Biology
https://read.qxmd.com/read/34635194/headache-in-adhd-as-comorbidity-and-a-side-effect-of-medications-a-systematic-review-and-meta-analysis
#15
REVIEW
Pei-Yin Pan, Ulf Jonsson, Sabriye Selin Şahpazoğlu Çakmak, Alexander Häge, Sarah Hohmann, Hjalmar Nobel Norrman, Jan K Buitelaar, Tobias Banaschewski, Samuele Cortese, David Coghill, Sven Bölte
There is mixed evidence on the association between headache and attention-deficit/hyperactivity disorder (ADHD), as well as headache and ADHD medications. This systematic review and meta-analysis investigated the co-occurrence of headache in children with ADHD, and the effects of ADHD medications on headache. Embase, Medline and PsycInfo were searched for population-based and clinical studies comparing the prevalence of headache in ADHD and controls through January 26, 2021. In addition, we updated the search of a previous systematic review and network meta-analysis of double-blind randomized controlled trials (RCTs) on ADHD medications on June 16, 2020...
January 2022: Psychological Medicine
https://read.qxmd.com/read/34534876/drugs-for-patients-with-epilepsy-and-excessive-daytime-sleepiness
#16
REVIEW
Gaetano Zaccara, Emanuele Bartolini, Luciana Tramacere, Simona Lattanzi
Excessive daytime sleepiness (EDS) and attentional deficits are often observed in people with epilepsy. They may be the consequence of seizures and subclinical discharges as well as of comorbid conditions as obstructive sleep apnea/hypopnea syndrome (OSAS), attention deficit hyperactivity disorder (ADHD), or other less frequent disorders. Excessive daytime sleepiness may also be caused or worsened by antiseizure medications (ASMs). Several meta-analyses suggested that lamotrigine, lacosamide, and perhaps eslicarbazepine are less sedative than other traditional and new ASMs and, in patients prone to somnolence, might be preferred over ASMs with more sedative properties...
September 14, 2021: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/33751683/cognitive-boosting-interventions-for-impulsivity-in-addiction-a-systematic-review-and-meta-analysis-of-cognitive-training-remediation-and-pharmacological-enhancement
#17
REVIEW
Alexandra C Anderson, George J Youssef, Alex H Robinson, Dan I Lubman, Antonio Verdejo-Garcia
AIMS: To evaluate and compare the effects of three cognitive boosting intervention approaches (computerised cognitive training, cognitive remediation and pharmacological cognitive enhancers) on measures of impulsive action and impulsive choice. DESIGN: Systematic review and meta-analysis of publications that reported original controlled trials of cognitive boosting interventions. SETTING: Studies conducted anywhere in the world. No language restrictions were applied...
December 2021: Addiction
https://read.qxmd.com/read/33692297/modafinil-decreased-thalamic-activation-in-auditory-emotional-processing-a-randomized-controlled-functional-magnetic-resonance-imaging-study
#18
JOURNAL ARTICLE
Tomoko Hama, Michihiko Koeda, Yumiko Ikeda, Amane Tateno, Tokuhiro Kawara, Hidenori Suzuki, Yoshiro Okubo
BACKGROUND: Modafinil is effective for improving wakefulness and attention, is used to treat patients with narcolepsy as an approved drug in Japan, and has been reported to be effective in attention-deficit hyperactivity disorder. On the other hand, modafinil has been reported to induce emotional instability including mania, depression, and suicidal ideation. Such side effects may be related to changes in cognitive behavior by the influence of modafinil on cerebral function of emotional recognition...
March 9, 2021: Journal of Nippon Medical School
https://read.qxmd.com/read/33645313/stimulating-meditation-a-pre-registered-randomised-controlled-experiment-combining-a-single-dose-of-the-cognitive-enhancer-modafinil-with-brief-mindfulness-training
#19
RANDOMIZED CONTROLLED TRIAL
Emily M Thomas, Tom P Freeman, Patrick Poplutz, Kane Howden, Chandni Hindocha, Michael Bloomfield, Sunjeev K Kamboj
BACKGROUND: Mindfulness-meditation has a variety of benefits on well-being. However, individuals with primary attentional impairments (e.g. attention deficit disorder) or attentional symptoms secondary to anxiety, depression or addiction, may be less likely to benefit, and require additional mindfulness-augmenting strategies. AIMS: To determine whether a single dose of the cognitive enhancer, modafinil, acutely increases subjective and behavioural indices of mindfulness, and augments brief mindfulness training...
June 2021: Journal of Psychopharmacology
https://read.qxmd.com/read/33531850/profile-of-solriamfetol-in-the-management-of-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea-focus-on-patient-selection-and-perspectives
#20
REVIEW
Vivien C Abad
Excessive sleepiness (ES) is a symptom of obstructive sleep apnea (OSA) and narcolepsy that has severe consequences. Wake-promoting drugs and stimulants are utilized as accessory treatment in OSA to reduce propensity to sleep but they do not improve sleep-disordered breathing. Solriamfetol is a first-line therapeutic agent to combat sleepiness in OSA and narcolepsy patients that is approved both by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For excessively sleepy adult patients with OSA despite primary treatment or narcolepsy patients without cataplexy, solriamfetol may be used as initial therapy or as replacement therapy in patients who fail treatment or experience unacceptable side effects with modafinil, armodafinil, pitolisant, or stimulants...
2021: Nature and Science of Sleep
keyword
keyword
161742
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.